Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

M. Cavo*, F. Gay, M. Beksac, L. Pantani, M.T. Petrucci, M.A. Dimopoulos, L. Dozza, B. van der Holt, S. Zweegman, S. Oliva, V.H.J. van der Velden, E. Zamagni, G.A. Palumbo, F. Patriarca, V. Montefusco, M. Galli, V. Maisnar, B. Gamberi, M. Hansson, A. BelottiL. Pour, P. Ypma, M. Grasso, A. Croockewit, S. Ballanti, M. Offidani, I.D. Vincelli, R. Zambello, A.M. Liberati, N.F. Andersen, A. Broijl, R. Troia, A. Pascarella, G. Benevolo, M.D. Levin, G. Bos, H. Ludwig, S. Aquino, A.M. Morelli, K.L. Wu, R. Boersma, R. Hajek, M. Durian, P.A.V. Borne, T.C. di Toritto, T. Zander, G. Specchia, A. Waage, P. Gimsing, U.H. Mellqvist

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

113 Citations (Web of Science)
Original languageEnglish
Pages (from-to)E456-E468
Number of pages13
JournalThe Lancet Haematology
Volume7
Issue number6
DOIs
Publication statusPublished - 1 Jun 2020

Keywords

  • daratumumab
  • deletion
  • single
  • DARATUMUMAB
  • SINGLE
  • DELETION

Cite this